- Home
- CDTX vs SERA Comparison
CDTX vs SERA Comparison
Compare CDTX & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- SERA
- Stock Information
- Founded
- CDTX 2012
- SERA 2008
- Country
- CDTX United States
- SERA United States
- Employees
- CDTX N/A
- SERA N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- SERA Precision Instruments
- Sector
- CDTX Health Care
- SERA Health Care
- Exchange
- CDTX Nasdaq
- SERA Nasdaq
- Market Cap
- CDTX 207.4M
- SERA 208.7M
- IPO Year
- CDTX 2015
- SERA 2021
- Fundamental
- Price
- CDTX $21.54
- SERA $4.12
- Analyst Decision
- CDTX Strong Buy
- SERA
- Analyst Count
- CDTX 7
- SERA 0
- Target Price
- CDTX $32.20
- SERA N/A
- AVG Volume (30 Days)
- CDTX 91.1K
- SERA 150.9K
- Earning Date
- CDTX 11-07-2024
- SERA 03-19-2025
- Dividend Yield
- CDTX N/A
- SERA N/A
- EPS Growth
- CDTX N/A
- SERA N/A
- EPS
- CDTX N/A
- SERA N/A
- Revenue
- CDTX $44,653,000.00
- SERA $94,000.00
- Revenue This Year
- CDTX N/A
- SERA N/A
- Revenue Next Year
- CDTX N/A
- SERA $3,081.82
- P/E Ratio
- CDTX N/A
- SERA N/A
- Revenue Growth
- CDTX 44.48
- SERA N/A
- 52 Week Low
- CDTX $10.00
- SERA $3.84
- 52 Week High
- CDTX $28.42
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- CDTX 48.34
- SERA 31.08
- Support Level
- CDTX $20.50
- SERA $3.89
- Resistance Level
- CDTX $24.95
- SERA $4.46
- Average True Range (ATR)
- CDTX 1.66
- SERA 0.43
- MACD
- CDTX 0.20
- SERA -0.00
- Stochastic Oscillator
- CDTX 50.36
- SERA 10.22
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.